LSE creators

Number of items: 49.
European Institute
  • Sorenson, Corinna, Kanavos, Panos (2011). Medical technology procurement in Europe: a cross-country comparison of current practice and policy. Health Policy, 100(1), 43-50. https://doi.org/10.1016/j.healthpol.2010.08.001
    • LSE
  • Sorenson, Corinna (2007). Quality measurement and assurance of long-term care for older people. Euro Observer, 9(2), 1-4.
    • LSE Health
  • Sorenson, Corinna, Gusmano, M., Oliver, Adam (2014). The politics of comparative effectiveness research: lessons from recent history. Journal of Health Politics, Policy and Law, 39(1), 139-170. https://doi.org/10.1215/03616878-2395199
  • Sorenson, Corinna, Drummond, Michael, Wilkinson, Grahame (2013). Use of innovation payments to encourage the adoption of new medical technologies in the English NHS. Health Policy and Technology, 2(3), 168-173. https://doi.org/10.1016/j.hlpt.2013.05.001
  • Sorenson, Corinna, Drummond, Michael, Bhuiyan Kahn, Beena (2013). Medical technology as a key driver of rising health expenditures: disentangling the relationship. Clinicoeconomics and Outcomes Research, 2013(5), 223-234. https://doi.org/10.2147/CEOR.S39634
  • Sorenson, Corinna, Drummond, Michael, Burns, Lawton R. (2013). Evolving reimbursement and pricing policies for devices in Europe and the United States should encourage greater value. Health Affairs, 32(4), 788-796. https://doi.org/10.1377/hlthaff.2012.1210
  • Sorenson, Corinna, Drummond, Mike, Chalkidou, Kalipso (2012). Comparative effectiveness research: the experience of the National Institute for Health and Clinical Excellence. Journal of Clinical Oncology, 30(34), 4267-4274. https://doi.org/10.1200/JCO.2012.42.1974
  • Sorenson, Corinna (2012). Valuing end-of-life care in the United States: the case of new cancer drugs. Health Economics, Policy and Law, 7(04), 411-430. https://doi.org/10.1017/S1744133112000217
  • Sorenson, Corinna, Drummond, Mike (2012). The socioeconomic value of orthopaedic devices: evidence and methodological and challenges. Orthopaedic Research and Reviews, 2012(4), 87-96. https://doi.org/10.2147/ORR.S32453
  • Towse, A, Drummond, Michael, Sorenson, Corinna (2012). Measuring value: pharmacoeconomics theory and practice. In Danzon, Patricia M., Nicholson, Sean (Eds.), Oxford Handbook on the Economics of the Biopharmaceutical Industry (pp. 394-437). Oxford University Press.
  • Sorenson, Corinna, Chalkidou, K. (2012). Reflections on the evolution of health technology assessment in Europe. Health Economics, Policy and Law, 7(1 (S)), 25-45. https://doi.org/10.1017/S1744133111000296
  • Sorenson, Corinna, Naci, Huseyin, Cylus, Jonathan, Mossialos, Elias (2011). Evidence of comparative efficacy should have a formal role in European drug approvals. British Medical Journal, 343(7822), d4849-d4849. https://doi.org/10.1136/bmj.d4849
  • Towse, Adrian, Drummond, Michael, Sorenson, Corinna (2011). Measuring value: pharmacoeconomics in theory and practice. (Occasional paper 11/03). Office of Health Economics (London, England).
  • Sorenson, Corinna, Tarricone, Rosanna, Siebert, Markus, Drummond, Michael (2011). Applying health economics for policy decision making: how much do devices differ from drugs? Europace, 13, 1154-1158. https://doi.org/10.1093/europace/eur089
  • Sorenson, Corinna, Kanavos, Panos (2011). Medical technology procurement in Europe: a cross-country comparison of current practice and policy. Health Policy, 100(1), 43-50. https://doi.org/10.1016/j.healthpol.2010.08.001
  • Barnett, Tony, Sorenson, Corinna (2011). Infectious disease surveillance in the United States and the United Kingdom: from public goods to the challenges of new technologies. Journal of Health Politics, Policy and Law, 36(1), 165-185. https://doi.org/10.1215/03616878-1191144
  • Sorenson, Corinna (2010). Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison. (Issue brief). The Commonwealth Fund.
  • Mladovsky, Philipa, Sorenson, Corinna (2010). Public financing of IVF: a review of policy rationales. Health Care Analysis, 18(2), 113-128. https://doi.org/10.1007/s10728-009-0114-3
  • Drummond, Michael, Sorenson, Corinna (2009). Use of pharmacoeconomics in drug reimbursement in Australia, Canada and the UK: what can we learn from international experience? In Arnold, Renee J. G. (Ed.), Pharmacoeconomics: From Theory to Practice (pp. 175-196). CRC Press.
  • Drummond, Michael, Sorenson, Corinna (2009). Nasty or nice?: a perspective on the use of health technology assessment in the United Kingdom. Value in Health, 12(S2), S8-S13. https://doi.org/10.1111/j.1524-4733.2009.00552.x
  • Sorenson, Corinna, Oliver, Adam (2009). The limitations and challenges to the economic evaluation of health technologies. In Costa-i-Font, Joan, Courbage, Christophe, McGuire, Alistair (Eds.), The Economics of New Health Technologies: Incentives, Organization, and Financing (pp. 205-216). Oxford University Press. https://doi.org/10.1093/acprof:oso/9780199550685.003.0013
  • Oliver, Adam, Sorenson, Corinna (2009). The limits and challenges to the economic evaluation of health technologies. In Costa-i-Font, Joan, Courbage, Christophe, McGuire, Alistair (Eds.), The Economics of New Health Technologies: Incentives, Organization, and Financing (pp. 205-218). Oxford University Press.
  • Drummond, Michael, Sorenson, Corinna (2009). Can NICE be nicer?: in a world of budget constraints there are no easy solutions. Value in Health, 12(5), 634-636. https://doi.org/10.1111/j.1524-4733.2009.00540.x
  • Sorenson, Corinna, Kanavos, Panos, Karamalis, M. (2009). HTA in Central and Eastern Europe: current status, challenges and opportunities. Journal of Medical Device Regulation, 6(1), 34-45.
  • Sorenson, Corinna (2009). Product development partnerships (PDPs) for neglected diseases: considerations on governance. Health Economics, Policy and Law, 4(1), 1-10. https://doi.org/10.1017/S1744133108004702
  • Sorenson, Corinna, Kanavos, Panos (2009). Topic 1: financing medical devices in France and the UK. European Health Technology Institute on Socio-Economic Research.
  • Sorenson, Corinna (2009). The role of HTA in coverage and pricing decisions: a cross-country comparison. Euro Observer, 11(1), 1-4.
  • Sorenson, Corinna, Drummond, Michael, Kanavos, Panos, McGuire, Alistair (2008). Does the work of the National Institute for Health and Clinical Excellence (NICE) have any relevance for the United States? ISPOR Connections, 14(4), 7-9.
  • Sorenson, Corinna (2008). Financing of medical technologies in Europe: the case of the UK and France. The European Health Technology Institute for Socio-Economic Research, London School of Economics.
  • Oliver, Adam, Sorenson, Corinna (2008). Importance of preference reversals in the valuation of health and healthcare. Expert Review of Pharmacoeconomics and Outcomes Research, 8(2), 95-99. https://doi.org/10.1586/14737167.8.2.95
  • Sorenson, Corinna, Drummond, Michael, Kanavos, Panos, McGuire, Alistair (2008). National Institute for Health and Clinical Excellence (NICE). How does it work and what are the implications for the U.S? National Pharmaceutical Council.
  • Sorenson, Corinna, Drummond, Michael, Kristensen, Finn Børlum, Busse, Reinhard (2008). How can the impact of health technology assessments be enhanced? (Health systems and policy analysis). World Health Organization.
  • Oliver, Adam, Sorenson, Corinna (2008). On equity in the English National Health Service. Harvard Health Policy Review, 8(2), 100-107.
  • Sorenson, Corinna (2008). The procurement landscape for medical devices in England: recent developments and applications to wound care. Eurohealth, 14(3), 4-6.
  • Martin, Greg, Sorenson, Corinna, Faunce, Thomas (2007). Balancing intellectual monopoly privileges and the need for essential medicines. Globalization and Health, 3(4). https://doi.org/10.1186/1744-8603-3-4
  • Sorenson, Corinna, Mossialos, Elias (2007). Measuring quality and standards of long-term care for older people. (Research note). European Commission.
  • Sorenson, Corinna, Drummond, Michael, Kanavos, Panos (2007-02-07 - 2007-02-08) Ensuring value for money in health care: The role of HTA in the European Union [Paper]. Financing sustainable healthcare in Europe: New approaches for new outcomes, Helsinki, Finland, FIN.
  • Allin, Sara, Masseria, Cristina, Sorenson, Corinna, Papanicolas, Irene, Mossialos, Elias (2007). Measuring inequalities in access to health care: a review of the indices? European Commission.
  • Masseria, Cristina, Allin, Sara, Sorenson, Corinna, Papanicolas, Irene, Mossialos, Elias (2007). What are the methodological issues related to measuring health and drawing comparisons across countries? European Commission.
  • Sorenson, Corinna, Mladovsky, Philipa (2006). Assisted reproduction technologies in Europe: an overview. (Research note). European Commission.
  • Sorenson, Corinna (2006). ART in the European Union. Euro Observer, 8(4), 1-8.
  • Sorenson, Corinna, Mladovsky, Philipa (2006). ART treatment in the EU: NICE guidelines for infertility treatment. Euro Observer, 8(4), p. 8.
  • Sorenson, Corinna (2006). Children's lifestyles in Europe. Eurohealth, 12(2), 21-22.
  • Sorenson, Corinna (2006). IVF/ART funding and reimbursement. Euro Observer, 8(4), 6-8.
  • Sorenson, Corinna, Mladovsky, Philipa (2006). NICE guidelines for fertility treatment. Euro Observer, 8(4), p. 8.
  • Martin, Greg, Sorenson, Corinna (2006). TRIPS, trade, and tablets for all: balancing intellectual property and the demand for medicine. In The Commonwealth Health Ministers Reference Book (pp. 53-57). Henley Media Group Ltd.
  • Sorenson, Corinna, Gemmen, Eric (2004). Development of a health economic model to demonstrate the costs and morbidity implications of an investigational obesity drug: technical report prepared for a US pharmaceutical company. The Lewin Group.
  • Sorenson, Corinna, Robboy, E. (2004). An innovative approach to post-market surveillance of emerging adverse events. US Food and Drug Administration.
    • Lifecourse, Ageing & Population Health
  • Sorenson, Corinna, Naci, Huseyin, Cylus, Jonathan, Mossialos, Elias (2011). Evidence of comparative efficacy should have a formal role in European drug approvals. British Medical Journal, 343(7822), d4849-d4849. https://doi.org/10.1136/bmj.d4849
    • Management
  • Sorenson, Corinna, Drummond, Michael (2014). Improving medical device regulation: the United States and Europe in perspective. The Milbank Quarterly, 92(1), 114-150. https://doi.org/10.1111/1468-0009.12043
    • Social Policy
  • Sorenson, Corinna (2015). Toward effective health technology regulation [Doctoral thesis]. London School of Economics and Political Science. picture_as_pdf
  • Sorenson, Corinna, Naci, Huseyin, Cylus, Jonathan, Mossialos, Elias (2011). Evidence of comparative efficacy should have a formal role in European drug approvals. British Medical Journal, 343(7822), d4849-d4849. https://doi.org/10.1136/bmj.d4849
  • Sorenson, Corinna, Kanavos, Panos (2011). Medical technology procurement in Europe: a cross-country comparison of current practice and policy. Health Policy, 100(1), 43-50. https://doi.org/10.1016/j.healthpol.2010.08.001
  • Sorenson, Corinna, Kanavos, Panos (2009). Topic 1: financing medical devices in France and the UK. European Health Technology Institute on Socio-Economic Research.
  • Oliver, Adam, Sorenson, Corinna (2008). Importance of preference reversals in the valuation of health and healthcare. Expert Review of Pharmacoeconomics and Outcomes Research, 8(2), 95-99. https://doi.org/10.1586/14737167.8.2.95
  • Oliver, Adam, Sorenson, Corinna (2008). On equity in the English National Health Service. Harvard Health Policy Review, 8(2), 100-107.
  • Sorenson, Corinna, Mossialos, Elias (2007). Measuring quality and standards of long-term care for older people. (Research note). European Commission.
  • Allin, Sara, Masseria, Cristina, Sorenson, Corinna, Papanicolas, Irene, Mossialos, Elias (2007). Measuring inequalities in access to health care: a review of the indices? European Commission.
  • Masseria, Cristina, Allin, Sara, Sorenson, Corinna, Papanicolas, Irene, Mossialos, Elias (2007). What are the methodological issues related to measuring health and drawing comparisons across countries? European Commission.